A detailed history of Dynamic Technology Lab Private LTD transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Dynamic Technology Lab Private LTD holds 18,095 shares of MRSN stock, worth $40,170. This represents 0.0% of its overall portfolio holdings.

Number of Shares
18,095
Holding current value
$40,170
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$1.23 - $2.25 $22,256 - $40,713
18,095 New
18,095 $34,000
Q2 2023

Aug 14, 2023

SELL
$3.08 - $9.55 $17,149 - $53,174
-5,568 Reduced 30.2%
12,869 $42,000
Q1 2023

May 12, 2023

SELL
$4.0 - $7.02 $24,384 - $42,793
-6,096 Reduced 24.85%
18,437 $76,000
Q4 2022

Feb 13, 2023

SELL
$5.65 - $7.86 $40,482 - $56,316
-7,165 Reduced 22.6%
24,533 $144,000
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $50,291 - $86,896
10,862 Added 52.13%
31,698 $214,000
Q2 2022

Aug 12, 2022

BUY
$2.84 - $5.0 $10,817 - $19,045
3,809 Added 22.37%
20,836 $96,000
Q1 2022

May 16, 2022

SELL
$3.74 - $6.63 $59,256 - $105,045
-15,844 Reduced 48.2%
17,027 $68,000
Q4 2021

Feb 14, 2022

BUY
$5.48 - $9.86 $180,133 - $324,108
32,871 New
32,871 $204,000
Q3 2021

Nov 15, 2021

SELL
$8.56 - $14.47 $169,667 - $286,809
-19,821 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$13.28 - $18.07 $263,222 - $358,165
19,821 New
19,821 $269,000
Q2 2020

Aug 14, 2020

SELL
$5.24 - $23.4 $81,345 - $363,261
-15,524 Closed
0 $0
Q1 2020

May 13, 2020

BUY
$4.41 - $9.28 $68,460 - $144,062
15,524 New
15,524 $91,000
Q4 2019

Feb 14, 2020

SELL
$1.45 - $6.73 $17,069 - $79,225
-11,772 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$1.54 - $4.2 $18,128 - $49,442
11,772 New
11,772 $19,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $216M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Dynamic Technology Lab Private LTD Portfolio

Follow Dynamic Technology Lab Private LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dynamic Technology Lab Private LTD, based on Form 13F filings with the SEC.

News

Stay updated on Dynamic Technology Lab Private LTD with notifications on news.